Myostatin deficiency partially rescues the bone phenotype of osteogenesis imperfecta model mice

@article{Oestreich2015MyostatinDP,
  title={Myostatin deficiency partially rescues the bone phenotype of osteogenesis imperfecta model mice},
  author={Arin K. Oestreich and Stephanie M. Carleton and Xiaomei Yao and Bettina A. Gentry and Catherine Raw and Marybeth Brown and Ferris M. Pfeiffer and Yong Wang and Charlotte L Phillips},
  journal={Osteoporosis International},
  year={2015},
  volume={27},
  pages={161-170}
}
SummaryMice with osteogenesis imperfecta (+/oim), a disorder of bone fragility, were bred to mice with muscle over growth to test whether increasing muscle mass genetically would improve bone quality and strength. The results demonstrate that femora from mice carrying both mutations have greater mechanical integrity than their +/oim littermates.IntroductionOsteogenesis imperfecta is a heritable connective tissue disorder due primarily to mutations in the type I collagen genes resulting in… Expand
Decreasing maternal myostatin programs adult offspring bone strength in a mouse model of osteogenesis imperfecta
TLDR
It is demonstrated that maternal deficiency of myostatin can enhance bone biomechanical strength and integrity in control and osteogenesis imperfecta mouse offspring, and provides evidence that bone is responsive to developmental programming and that mystatin can mediate these effects. Expand
Impact of Genetic and Pharmacologic Inhibition of Myostatin in a Murine Model of Osteogenesis Imperfecta
TLDR
Musculoskeletal outcomes of geneticMyostatin deficiency and postnatal pharmacological myostatin inhibition by a monoclonal anti‐myostatin antibody in the G610C mouse, a model of mild–moderate type I/IV human OI are determined. Expand
Novel ActRIIB ligand trap increases muscle mass and improves bone geometry in a mouse model of severe osteogenesis imperfecta.
TLDR
Data indicate that activin A/myostatin neutralizing antibody ACE-2494 is effective in stimulating muscle mass, bone length and diaphyseal bone growth but does not correct bone mass phenotype in a mouse model ofdominant OI. Expand
Osteogenesis Imperfecta: Muscle–Bone Interactions when Bi-directionally Compromised
TLDR
Muscle and bone are both compromised in OI, making it essential to understand the mechanisms responsible for both impaired muscle and bone functions and their interdependence, as this will expand and drive new physiotherapeutic and pharmacological approaches to treat OI and other musculoskeletal disorders. Expand
Skeletal Response to Soluble Activin Receptor Type IIB in Mouse Models of Osteogenesis Imperfecta
TLDR
The data suggest that sActRIIB‐mFc may provide a new therapeutic direction to improve both bone and muscle properties in OI, and the improved cortical bone geometry and biomechanical integrity reflect an anabolic effect due to increased mineral apposition and bone formation rates. Expand
Muscle abnormalities in osteogenesis imperfecta
TLDR
Interventions targeting muscle mass have shown encouraging results in OI animal models and are an interesting area for further research. Expand
Muscle contraction induces osteogenic levels of cortical bone strain despite muscle weakness in a mouse model of Osteogenesis Imperfecta.
TLDR
Results indicated that the relationship between maximum muscle torque and maximum engendered strain is altered in oim/oim bone, with less torque required to engender strain compare to wild-type and heterozygous mice. Expand
Impact of Intrinsic Muscle Weakness on Muscle–Bone Crosstalk in Osteogenesis Imperfecta
TLDR
This review will highlight how impaired skeletal muscle function contributes to the pathophysiology of OI and how this phenomenon further perpetuates bone fragility. Expand
Signaling pathways affected by mutations causing osteogenesis imperfecta.
TLDR
An overview of signaling pathways that are associated with known OI-causing genes and the impact of these genes on signal transduction are discussed, which include WNT-, RANK/RANKL-, TGFβ-, MAPK- and integrin-mediated signaling as well as the unfolded protein response. Expand
Muscle-Bone Interactions in Pediatric Bone Diseases
TLDR
Considering muscle-bone interactions does not only contribute to the understanding of musculoskeletal disorders but also can identify new targets for therapeutic interventions. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 50 REFERENCES
Impaired Osteoblastogenesis in a Murine Model of Dominant Osteogenesis Imperfecta: A New Target for Osteogenesis Imperfecta Pharmacological Therapy
TLDR
This is the first report of impaired MSC differentiation to osteoblasts in OI, and it identifies a new potential target for the pharmacological treatment of the disorder. Expand
Skeletal muscle weakness in osteogenesis imperfecta mice.
TLDR
Exercise intolerance, muscle fatigue and weakness are often-reported, little-investigated concerns of patients with osteogenesis imperfecta and muscle weakness in oim mice reflects inherent skeletal muscle pathology. Expand
Comparison of bone tissue properties in mouse models with collagenous and non-collagenous genetic mutations using FTIRI.
TLDR
It is demonstrated that abnormal extracellular matrix assembly plays a role in the bone fragility in both the fro/fro and oim/oim genotypes of OI. Expand
A myostatin and activin decoy receptor enhances bone formation in mice.
TLDR
It is demonstrated that ActRIIB-Fc increases both muscle and bone mass in mice and a therapeutic that has this dual activity represents a potential approach for the treatment of frailty. Expand
Bone Mineral Content and Density in the Humerus of Adult Myostatin-Deficient Mice
TLDR
The results suggest that the effects of increased muscle mass on the mouse humerus are localized to regions where muscles attach; furthermore, these effects include increased mineral content of both trabecular and cortical bone. Expand
Gender-Dependence of Bone Structure and Properties in Adult Osteogenesis Imperfecta Murine Model
TLDR
Evidence is provided of the importance of gender in the evaluation and interpretation of potential therapeutic strategies when using mouse models of OI and the mineral/matrix composition and hydroxyproline content of bone were influenced primarily by the oim collagen mutation. Expand
Myostatin (GDF-8) as a key factor linking muscle mass and bone structure.
TLDR
The data suggest that myostatin has direct effects on the proliferation and differentiation of osteoprogenitor cells, and that hisostatin antagonists and inhibitors are likely to enhance both muscle mass and bone strength. Expand
Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice: a model of human osteogenesis imperfecta.
TLDR
A strain of mice with a nonlethal recessively inherited mutation (oim) that results in phenotypic and biochemical features that simulate moderate to severe human OI is described, and the oim mouse will facilitate the study of type I collagen-related skeletal disease. Expand
Increased bone mineral density in the femora of GDF8 knockout mice.
  • M. Hamrick
  • Medicine
  • The anatomical record. Part A, Discoveries in molecular, cellular, and evolutionary biology
  • 2003
TLDR
Results suggest that inhibitors of GDF8 function may be useful pharmacological agents for increasing both muscle mass and BMD. Expand
First Mouse Model for Combined Osteogenesis Imperfecta and Ehlers‐Danlos Syndrome
  • Frieda Chen, Ruolin Guo, +12 authors J. Aubin
  • Biology, Medicine
  • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2014
TLDR
Col1a1Jrt/+ mice are the first reported model of combined OI/EDS and will be useful for exploring aspects of OI and EDS pathophysiology and treatment. Expand
...
1
2
3
4
5
...